{"id":"https://openalex.org/W1994288384","doi":"https://doi.org/10.1093/eurjhf/hfr034","title":"Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study","display_name":"Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study","publication_year":2011,"publication_date":"2011-04-05","ids":{"openalex":"https://openalex.org/W1994288384","doi":"https://doi.org/10.1093/eurjhf/hfr034","mag":"1994288384","pmid":"https://pubmed.ncbi.nlm.nih.gov/21467028"},"language":"en","primary_location":{"id":"doi:10.1093/eurjhf/hfr034","doi":"https://doi.org/10.1093/eurjhf/hfr034","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurjhf/hfr034","pdf_url":null,"source":{"id":"https://openalex.org/S87609158","display_name":"European Journal of Heart Failure","issn_l":"1388-9842","issn":["1388-9842","1879-0844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Heart Failure","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042843111","display_name":"Bertram Pitt","orcid":"https://orcid.org/0000-0001-5880-275X","observed_orcids":["https://orcid.org/0000-0001-5880-275X","https://orcid.org/0000-0001-7703-0345"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bertram Pitt","raw_affiliation_strings":["University of Michigan , Ann Arbor, MI ,","University of Michigan Ann Arbor MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan , Ann Arbor, MI ,","institution_ids":["https://openalex.org/I27837315"]},{"raw_affiliation_string":"University of Michigan Ann Arbor MI, USA","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027518592","display_name":"Roberto Latini","orcid":"https://orcid.org/0000-0002-3729-4650","observed_orcids":["https://orcid.org/0000-0002-3729-4650"]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Roberto Latini","raw_affiliation_strings":["Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri , Milan ,","Department of Cardiovascular Research Istituto di Ricerche Farmacologiche Mario Negri  Milan Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri , Milan ,","institution_ids":["https://openalex.org/I19630809"]},{"raw_affiliation_string":"Department of Cardiovascular Research Istituto di Ricerche Farmacologiche Mario Negri  Milan Italy","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088186128","display_name":"Aldo Pietro Maggioni","orcid":"https://orcid.org/0000-0003-2764-6779","observed_orcids":["https://orcid.org/0000-0003-2764-6779"]},"institutions":[{"id":"https://openalex.org/I4210095959","display_name":"Associazione Nazionale Medici Cardiologi Ospedalieri","ror":"https://ror.org/00pyc4352","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210095959"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Aldo P. Maggioni","raw_affiliation_strings":["ANMCO Research Center , Florence ,","ANMCO Research Center Florence Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ANMCO Research Center , Florence ,","institution_ids":["https://openalex.org/I4210095959"]},{"raw_affiliation_string":"ANMCO Research Center Florence Italy","institution_ids":["https://openalex.org/I4210095959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054830306","display_name":"Scott David Solomon","orcid":"https://orcid.org/0000-0003-3698-9597","observed_orcids":["https://orcid.org/0000-0003-3698-9597"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott D. Solomon","raw_affiliation_strings":["Brigham & Women's Hospital , Boston, MA ,","Brigham & Women's Hospital Boston MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham & Women's Hospital , Boston, MA ,","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"Brigham & Women's Hospital Boston MA USA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105024498","display_name":"Beverly A. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Beverly A. Smith","raw_affiliation_strings":["Novartis Pharma AG , Basel ,","Novartis Pharma AG, Basel, SWITZERLAND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG , Basel ,","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, SWITZERLAND","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052954074","display_name":"Melanie Wright","orcid":"https://orcid.org/0000-0001-7931-3947","observed_orcids":["https://orcid.org/0000-0001-7931-3947"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Melanie Wright","raw_affiliation_strings":["Novartis Pharma AG , Basel ,","Novartis Pharma AG, Basel, SWITZERLAND"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG , Basel ,","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, SWITZERLAND","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012641937","display_name":"MARGARET FORNEY PRESCOTT","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret F. Prescott","raw_affiliation_strings":["Novartis Pharmaceutical Corporation , East Hanover, NJ ,","Novartis Pharmaceutical Corporation East Hanover NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceutical Corporation East Hanover NJ USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027213857","display_name":"John J.V. McMurray","orcid":"https://orcid.org/0000-0002-6317-3975","observed_orcids":["https://orcid.org/0000-0002-6317-3975"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I32003884","display_name":"British Heart Foundation","ror":"https://ror.org/02wdwnk04","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I32003884"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB","US"],"is_corresponding":true,"raw_author_name":"John J.V. McMurray","raw_affiliation_strings":["Brigham & Women's Hospital , Boston, MA ,","British Heart Foundation Cardiovascular and Research Centre, University of Glasgow , 126 University Place, Glasgow, G12 8TA ,","Brigham & Women's Hospital Boston MA USA","British Heart Foundation Cardiovascular and Research Centre University of Glasgow 126 University Place Glasgow G12 8TA UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham & Women's Hospital , Boston, MA ,","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"British Heart Foundation Cardiovascular and Research Centre, University of Glasgow , 126 University Place, Glasgow, G12 8TA ,","institution_ids":["https://openalex.org/I32003884","https://openalex.org/I7882870"]},{"raw_affiliation_string":"Brigham & Women's Hospital Boston MA USA","institution_ids":["https://openalex.org/I1283280774"]},{"raw_affiliation_string":"British Heart Foundation Cardiovascular and Research Centre University of Glasgow 126 University Place Glasgow G12 8TA UK","institution_ids":["https://openalex.org/I32003884","https://openalex.org/I7882870"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5027213857"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I32003884","https://openalex.org/I7882870"],"apc_list":{"value":5300,"currency":"USD","value_usd":5300},"apc_paid":null,"fwci":2.853,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.91199846,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"13","issue":"7","first_page":"755","last_page":"764"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.7562999725341797,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.7562999725341797,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.17599999904632568,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":0.032600000500679016,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aliskiren","display_name":"aliskiren","score":1.0},{"id":"https://openalex.org/keywords/mineralocorticoid-receptor-antagonists","display_name":"mineralocorticoid receptor antagonists","score":0.9110000133514404},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.7739999890327454},{"id":"https://openalex.org/keywords/renin-inhibitors","display_name":"renin inhibitors","score":0.8610000014305115},{"id":"https://openalex.org/keywords/brain-natriuretic-peptide","display_name":"brain natriuretic peptide","score":0.9929999709129333},{"id":"https://openalex.org/keywords/n-terminal-probnp","display_name":"N-terminal proBNP","score":0.9079999923706055},{"id":"https://openalex.org/keywords/plasma-renin-activity","display_name":"plasma renin activity","score":0.9919999837875366},{"id":"https://openalex.org/keywords/urinary-aldosterone","display_name":"urinary aldosterone","score":0.9909999966621399},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.7310000061988831},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.6430000066757202},{"id":"https://openalex.org/keywords/hypotension","display_name":"hypotension","score":0.9290000200271606},{"id":"https://openalex.org/keywords/hyperkalemia","display_name":"hyperkalemia","score":0.9309999942779541},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C2779838083","wikidata":"https://www.wikidata.org/wiki/Q414904","display_name":"Aliskiren","level":4,"score":0.9859344959259033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8494247198104858},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.7612351179122925},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7016192674636841},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6128829717636108},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4987938404083252},{"id":"https://openalex.org/C189135053","wikidata":"https://www.wikidata.org/wiki/Q3454531","display_name":"Mineralocorticoid receptor","level":3,"score":0.4924691617488861},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4700191020965576},{"id":"https://openalex.org/C2777425892","wikidata":"https://www.wikidata.org/wiki/Q409255","display_name":"Renin inhibitor","level":4,"score":0.4509153962135315},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.41511231660842896},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3892351984977722},{"id":"https://openalex.org/C2778525890","wikidata":"https://www.wikidata.org/wiki/Q184564","display_name":"Aldosterone","level":2,"score":0.35457998514175415},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.35426202416419983},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3390852212905884},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.18116044998168945},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000319","descriptor_name":"Adrenergic beta-Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000319","descriptor_name":"Adrenergic beta-Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000451","descriptor_name":"Mineralocorticoid Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D013223","descriptor_name":"Statistics as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013318","descriptor_name":"Stroke Volume","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016001","descriptor_name":"Confidence Intervals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016277","descriptor_name":"Ventricular Function, Left","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020097","descriptor_name":"Natriuretic Peptide, Brain","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1093/eurjhf/hfr034","doi":"https://doi.org/10.1093/eurjhf/hfr034","is_oa":false,"landing_page_url":"https://doi.org/10.1093/eurjhf/hfr034","pdf_url":null,"source":{"id":"https://openalex.org/S87609158","display_name":"European Journal of Heart Failure","issn_l":"1388-9842","issn":["1388-9842","1879-0844"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Heart Failure","raw_type":"journal-article"},{"id":"pmid:21467028","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21467028","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of heart failure","raw_type":"Journal Article"},{"id":"pmh:oai:deepblue.lib.umich.edu:2027.42/106150","doi":null,"is_oa":false,"landing_page_url":"https://deepblue.lib.umich.edu/bitstreams/9f02de44-8ecb-4359-9dd9-0829fa0f8b88/download","pdf_url":null,"source":{"id":"https://openalex.org/S4306400393","display_name":"Deep Blue (University of Michigan)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I27837315","host_organization_name":"University of Michigan","host_organization_lineage":["https://openalex.org/I27837315"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:researchbank.acu.edu.au:fhs_pub-7037","doi":null,"is_oa":false,"landing_page_url":"https://researchbank.acu.edu.au/fhs_pub/6038","pdf_url":null,"source":{"id":"https://openalex.org/S4306401783","display_name":"Research Bank (Australian Catholic University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I86695891","host_organization_name":"Australian Catholic University","host_organization_lineage":["https://openalex.org/I86695891"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Faculty of Health Sciences Publications","raw_type":"text"},{"id":"pmh:oai:eprints.gla.ac.uk:54361","doi":null,"is_oa":false,"landing_page_url":"http://eprints.gla.ac.uk/54361/","pdf_url":null,"source":{"id":"https://openalex.org/S4210235606","display_name":"ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)","issn_l":"2622-8912","issn":["2622-8912","2622-8920"],"is_oa":false,"is_in_doaj":true,"is_core":false,"listed_in":["doaj"],"host_organization":"https://openalex.org/I4405259220","host_organization_name":"Institut Agama Islam Negeri Langsa","host_organization_lineage":["https://openalex.org/I4405259220"],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Articles"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8600000143051147,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W158531677","https://openalex.org/W170303893","https://openalex.org/W1543680891","https://openalex.org/W1994079702","https://openalex.org/W2009279666","https://openalex.org/W2017666800","https://openalex.org/W2020860227","https://openalex.org/W2026881482","https://openalex.org/W2056893352","https://openalex.org/W2063624516","https://openalex.org/W2093276210","https://openalex.org/W2098780362","https://openalex.org/W2152094259","https://openalex.org/W2152798629","https://openalex.org/W2164705414","https://openalex.org/W2168907840","https://openalex.org/W2270092661","https://openalex.org/W2323458614","https://openalex.org/W2328926651","https://openalex.org/W2411868239","https://openalex.org/W3209204398"],"related_works":["https://openalex.org/W147860503","https://openalex.org/W2056076534","https://openalex.org/W1994079702","https://openalex.org/W1016248440","https://openalex.org/W2020061449","https://openalex.org/W2006078326","https://openalex.org/W2131178128","https://openalex.org/W2281074424","https://openalex.org/W2788252793","https://openalex.org/W2160191188"],"abstract_inverted_index":{"AIMS:":[0],"We":[1],"evaluated":[2],"the":[3,12,23,114,138,162],"influence":[4],"of":[5,17,26,92,140,167,202,251],"concomitant":[6,252],"mineralocorticoid":[7],"receptor":[8,64,132],"antagonists":[9],"(MRAs)":[10],"on":[11,94],"safety":[13],"and":[14,55,66,90,104,157,210,214,222,243],"neurohumoral":[15,95,248],"effects":[16,91],"a":[18],"direct":[19],"renin":[20,155],"inhibitor":[21,61],"in":[22,99,224,247],"ALiskiren":[24],"Observation":[25],"Heart":[27,40],"Failure":[28],"Treatment":[29],"(ALOFT)":[30],"study.":[31],"METHODS":[32],"AND":[33],"RESULTS:":[34],"Patients":[35],"with":[36,57,74],"stable":[37],"New":[38],"York":[39],"Association":[41],"class":[42],"II-IV":[43],"heart":[44],"failure":[45],"(HF),":[46],"plasma":[47,154],"B-type":[48],"natriuretic":[49],"peptide":[50],"(BNP)":[51],"concentration":[52],">100":[53],"pg/mL,":[54],"treated":[56],"an":[58],"angiotensin-converting":[59],"enzyme":[60],"(or":[62],"angiotensin":[63],"blocker)":[65],"\u03b2-blocker":[67],"were":[68,97,119,216],"randomized":[69,116],"to":[70,81,145,149,164,233],"once-daily,":[71],"double-blind":[72],"treatment":[73,110,122],"aliskiren":[75,93,141,175,189,221],"150":[76,142,230],"mg":[77,231],"or":[78],"placebo,":[79,127],"added":[80,144,232],"optimal":[82],"HF":[83,147,235],"therapy,":[84,148],"for":[85,170],"12":[86,241],"weeks.":[87],"Safety,":[88],"tolerability,":[89],"biomarkers":[96,249],"assessed":[98],"patients":[100],"who":[101],"received":[102],"(MRA+)":[103],"did":[105,135],"not":[106,136],"receive":[107],"(MRA-)":[108],"MRA":[109,121,226,253],"at":[111],"baseline.":[112],"Of":[113],"302":[115],"patients,":[117],"101":[118],"receiving":[120],"(aliskiren,":[123],"n":[124,128],"=":[125,129],"52;":[126],"49).":[130],"Mineralocorticoid":[131],"antagonist":[133],"status":[134],"affect":[137],"ability":[139],"mg,":[143],"standard":[146,234],"lower":[150],"BNP,":[151],"N-terminal":[152],"proBNP,":[153],"activity,":[156],"urinary":[158],"aldosterone.":[159],"For":[160],"example,":[161],"end-of-study":[163],"baseline":[165],"ratio":[166],"geometric":[168],"mean":[169],"BNP":[171],"was:":[172],"MRA+":[173],"group:":[174,188],"0.68":[176],"[95%":[177],"confidence":[178],"interval":[179],"(CI)":[180],"0.47,":[181],"0.98],":[182],"placebo":[183,193,223],"0.85":[184,194],"(0.58,":[185],"1.24);":[186],"MRA-":[187],"0.62":[190],"(0.45,":[191],"0.84),":[192],"(0.63,":[195],"1.15),":[196],"interaction":[197],"P=":[198],"0.720.":[199],"The":[200],"incidence":[201],"pre-specified":[203],"adverse":[204],"events":[205],"(renal":[206],"dysfunction,":[207],"symptomatic":[208],"hypotension,":[209],"hyperkalaemia)":[211],"was":[212,237],"low,":[213],"there":[215],"no":[217],"significant":[218],"differences":[219],"between":[220],"either":[225],"subgroup.":[227],"CONCLUSION:":[228],"Aliskiren":[229],"therapy":[236],"well":[238],"tolerated":[239],"over":[240],"weeks":[242],"provided":[244],"beneficial":[245],"changes":[246],"regardless":[250],"treatment.":[254]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}